HOME >> BIOLOGY >> NEWS
Outcome for acute lymphoblastic leukemia linked to gene expression patterns

A relatively small number of genes are linked to either resistance or sensitivity to four major cancer drugs used to treat acute lymphoblastic leukemia (ALL), suggesting that these genes are key to treatment outcome. This study, by investigators from St. Jude Children's Research Hospital and Erasmus University Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands, is published in the Aug. 4, 2004 issue of the New England Journal of Medicine (NEJM).

The researchers identified four groups of genes, each of which had a characteristic pattern of expression in leukemia cells depending on whether they were sensitive or resistant to four widely used antileukemic agents. Investigators found that the expression pattern of these genes was significantly related to treatment outcome.

The study identified 123 previously unrecognized genes that are associated with resistance to cancer chemotherapy. Only three of these genes had been previously linked to drug resistance. These new genes represent potential targets for new agents that could be developed to overcome resistance to drugs currently used to treat ALL.

Despite the pioneering role of St. Jude in increasing the cure rate of childhood ALL from 4 percent to more than 80 percent during the past 40 years, the cause of failure in the remaining 20 percent of children is largely unknown, according to William E. Evans, Pharm.D., St. Jude scientific director. The current findings could help further reduce the number of failures. Evans is a senior author of the NEJM report.

"We've known for years that certain genetic changes in leukemic cells are associated with a high risk of treatment failure," Evans said. "But we also realized that many children who have an unfavorable genetic subtype of ALL are cured, and many patients whose genetic subtype was considered to be favorable weren't cured. The findings of this study are helping us understand
'"/>

Contact: Bonnie Cameron
bonnie.cameron@stjude.org
901-495-4815
St. Jude Children's Research Hospital
4-Aug-2004


Page: 1 2 3

Related biology news :

1. High Temperature Immediately Following A Stroke Leads To Worse Outcome; Quick Cooling Shown To Have Benefit
2. Surgical Experience Improves Thyroidectomy Outcome
3. Chromosomal Abnormalities Key For Prediting Leukemia Outcome
4. Colorado State Biology Professor Says Fatty Acids, Not Shadow, Determine Outcome Of Groundhog Day Feb. 2
5. Gene profiles could improve acute leukemia diagnosis and lead to better treatments
6. Scientists discover molecular target for treatment of T cell acute lymphoblastic leukemia
7. Bat saliva drug and new MRI techniques offer hope for acute stroke treatment
8. Mutation may help cause acute myeloid leukemia
9. Cox-2 enzyme plays important role regulating acute pancreatitis and associated lung injury
10. UT Southwestern researchers say overdoses of acetaminophen cause most cases of acute liver failure
11. World Trade Center clean-up workers report acute respiratory problems

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/12/2019)... ... April 11, 2019 , ... Neal O’Farrell is one of the first ... He is executive director of the consumer advocacy non-profit the Identity Theft Council as ... member of the Federal Communications Commission’s Cybersecurity Roundtable and is currently a fellow of ...
(Date:4/5/2019)... AUBURN, Mass. (PRWEB) , ... April 04, 2019 ... ... family is available with integrated linear encoders providing 0.05 microns and 0.005 microns ... prices. Many motor and drive variations are available, from fast DC-servo motors with ...
(Date:4/4/2019)... ... 03, 2019 , ... R3 Stem Cell is now offering ... of Excellence. R3 wants patients to feel secure when they make a significant ... Centers that use inferior regenerative biologics, protocols or amounts, R3 provides a safe ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... ... April 09, 2019 , ... ... the capacity of life sciences organizations to accelerate innovation and maximize productivity, announces ... in the past 12 months. , USDM’s Cloud Assurance is a ...
(Date:4/8/2019)... (PRWEB) , ... April 08, 2019 , ... US ... investors a $15 million preferred equity investment in the privately held pharmaceutical company, S1 ... leading drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready ...
(Date:3/29/2019)... ... March 28, 2019 , ... ... testing milestones, CARB-X has proceeded with a second stage of funding for Specific’s ... million, which is on top of the $1.7 million already awarded by CARB-X. ...
(Date:3/23/2019)... (PRWEB) , ... March 22, 2019 , ... ... sample collection, and analysis to a team of researchers at Nnamdi Azikiwe University ... by Dr. Nneka R. Agbokoba, PhD, of the Department of Medical Laboratory Sciences ...
Breaking Biology Technology:
Cached News: